(-)-Cevimeline hydrochloride risodium salt FLT1 (VEGFR1) and NTRK3 (TRKC)

FLT1 (VEGFR1) and NTRK3 (TRKC)

75-47-43(67)39(63)37(61)29(72-47)22-69-45-41(65)34(58)26(57)21-68-45)24-11-16-52(7)33(24)25(56)18-31-50(5)15-13-32(49(3

InChiKey: MTJLQTFHJIHXIX-GDUXWEAWSA-N

a novel plasminogen activator inhibitor-1 inhibitor

(-)-Cevimeline hydrochloride risodium salt FLT1 (VEGFR1) and NTRK3 (TRKC)( ) Cevimeline hydrochloride hemihydrate (( ) SNI 2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other tissues were investigated in mice, rats, guinea pigs, rabbits, and dogs. The in vitro metab. of SNI 2011 was also evaluated with rat and dog liver